Abdullah Algwizani

Abdullah Algwizani

Auto-generated profile, based on publicly available information

Abdullah Algwizani

Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AAAbdullah Algwizani
Abdullah Algwizani
MAMohammad Alzunitan
Mohammad Alzunitan
AAAhmad Alharbi
Ahmad Alharbi
AAAbdulrahman Alsaedy
Abdulrahman Alsaedy
SASameera Aljohani
Sameera Aljohani
AAAdel Alothman
Adel Alothman
Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide. This case-series describes our experience with ceftazidime-avibactam in the treatment of six cases with carbapenem-resistant organisms in King Abdulaziz Medical City in Riyadh, Saudi Arabia. After trying various combinations of antibiotic therapies without improvement, cases were treated with ceftazidime-avibactam. Five of the six achieved complete cure, both clinically and microbiologically.

28 April 2022 in Eastern Mediterranean Health Journal
Verified
Journal Article
Open access
JMJesse Malkin
Jesse Malkin
EFEric Finkelstein
Eric Finkelstein
DBDrishti Baid
Drishti Baid
AAAda Al-Qunaibet
Ada Al-Qunaibet
SASami Almudarra
Sami Almudarra
AAAbdullah Algwizani
Abdullah Algwizani
Background: The prevalence of noncommunicable diseases (NCDs) has been increasing in Saudi Arabia. Aims: Our objective was to estimate the effect of NCDs on direct medical costs and workforce productivity in Saudi Arabia. Methods: To estimate direct medical costs, we estimated the unit cost of treating 10 NCDs, then multiplied the unit cost by disease prevalence and summed across diseases. To estimate workforce productivity losses, we multiplied gross domestic product per person in the labour force by the loss in productivity from each NCD and the prevalence in the labour force of each NCD. Results: We estimated annual direct medical costs of 11.8 billion international dollars (Int$) for the 10 NCDs assessed (13.6% of total annual health expenditure). We estimated workforce productivity losses of Int$ 75.7 billion (4.5% of gross domestic product). Conclusion: The economic burden of NCDs in Saudi Arabia – particularly the effect on worker productivity – is substantial.